Eupraxia Pharmaceuticals (EPRX) Institutional Ownership

During the previous two years, 11 institutional investors and hedge funds held shares of Eupraxia Pharmaceuticals. The most heavily invested institutionals were Scotia Capital Inc. ($6.98M), Royal Bank of Canada ($1.13M), Bank of Montreal Can ($215K), Ingalls & Snyder LLC ($214K), JPMorgan Chase & Co. ($108K), Bank of America Corp DE ($72K), and Quadrature Capital Ltd ($61K).Learn more on Eupraxia Pharmaceuticals' institutional investors.

Of the 10 institutional investors that purchased Eupraxia Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Scotia Capital Inc. ($160.96K), Royal Bank of Canada ($59.68K), Ingalls & Snyder LLC ($37.20K), Raymond James Financial Inc. ($23.23K), JPMorgan Chase & Co. ($16.02K), 180 Wealth Advisors LLC ($13K), and Quadrature Capital Ltd ($10.70K).

Institutional investors have bought a total of 335,345 shares in the last 24 months. This purchase volume represents approximately $1.28M in transactions.

The following institutional investors have sold Eupraxia Pharmaceuticals stock in the last 24 months: Scotia Capital Inc. ($265.25K), TD Waterhouse Canada Inc. ($95.39K), and Bank of Montreal Can ($15K).

Institutional investors have sold a total of 375,638 shares in the last 24 months. This volume of shares sold represents approximately $2.15M in transactions.